<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>Chapter 14 Fluids, electrolytes &amp; acid-base | LATINART</title>
  <meta name="description" content="A brief index of the landmark trials in nephrology &amp; renal transplant." />
  <meta name="generator" content="bookdown 0.32 and GitBook 2.6.7" />

  <meta property="og:title" content="Chapter 14 Fluids, electrolytes &amp; acid-base | LATINART" />
  <meta property="og:type" content="book" />
  <meta property="og:image" content="/logo.png" />
  <meta property="og:description" content="A brief index of the landmark trials in nephrology &amp; renal transplant." />
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Chapter 14 Fluids, electrolytes &amp; acid-base | LATINART" />
  
  <meta name="twitter:description" content="A brief index of the landmark trials in nephrology &amp; renal transplant." />
  <meta name="twitter:image" content="/logo.png" />

<meta name="author" content="Robert W Hunter" />


<meta name="date" content="2024-07-09" />

  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="renovascular-disease.html"/>
<link rel="next" href="glomerular-disease.html"/>
<script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/fuse.js@6.4.6/dist/fuse.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />








<link href="libs/anchor-sections-1.1.0/anchor-sections.css" rel="stylesheet" />
<link href="libs/anchor-sections-1.1.0/anchor-sections-hash.css" rel="stylesheet" />
<script src="libs/anchor-sections-1.1.0/anchor-sections.js"></script>




<link rel="stylesheet" href="style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="https://www.kidneyfish.net">KidneyFish</a></li>
<li><a href="./">LATINART</a></li>

<li class="divider"></li>
<li class="chapter" data-level="" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i>Preface</a></li>
<li class="chapter" data-level="1" data-path="intro.html"><a href="intro.html"><i class="fa fa-check"></i><b>1</b> Introduction</a>
<ul>
<li class="chapter" data-level="1.1" data-path="intro.html"><a href="intro.html#types-of-study"><i class="fa fa-check"></i><b>1.1</b> Types of study</a></li>
<li class="chapter" data-level="1.2" data-path="intro.html"><a href="intro.html#other-lists-of-landmark-trials"><i class="fa fa-check"></i><b>1.2</b> Other lists of ‘landmark’ trials</a></li>
<li class="chapter" data-level="1.3" data-path="intro.html"><a href="intro.html#going-deeper"><i class="fa fa-check"></i><b>1.3</b> Going deeper</a></li>
<li class="chapter" data-level="1.4" data-path="intro.html"><a href="intro.html#recent-trials-see-twitter-feed"><i class="fa fa-check"></i><b>1.4</b> Recent trials: see Twitter feed</a></li>
</ul></li>
<li class="part"><span><b>I AKI</b></span></li>
<li class="chapter" data-level="2" data-path="aki.html"><a href="aki.html"><i class="fa fa-check"></i><b>2</b> AKI</a>
<ul>
<li class="chapter" data-level="2.1" data-path="aki.html"><a href="aki.html#aki-trials-in-other-chapters"><i class="fa fa-check"></i><b>2.1</b> AKI trials in other chapters</a></li>
<li class="chapter" data-level="2.2" data-path="aki.html"><a href="aki.html#association-of-aki-with-mortality-morbidity"><i class="fa fa-check"></i><b>2.2</b> Association of AKI with mortality &amp; morbidity</a></li>
<li class="chapter" data-level="2.3" data-path="aki.html"><a href="aki.html#other-trials-in-aki"><i class="fa fa-check"></i><b>2.3</b> Other trials in AKI</a></li>
</ul></li>
<li class="chapter" data-level="3" data-path="contrast-associated-nephropathy.html"><a href="contrast-associated-nephropathy.html"><i class="fa fa-check"></i><b>3</b> Contrast-associated nephropathy</a></li>
<li class="chapter" data-level="4" data-path="hepatorenal-syndrome.html"><a href="hepatorenal-syndrome.html"><i class="fa fa-check"></i><b>4</b> Hepatorenal syndrome</a>
<ul>
<li class="chapter" data-level="4.1" data-path="hepatorenal-syndrome.html"><a href="hepatorenal-syndrome.html#has-and-vasopressors"><i class="fa fa-check"></i><b>4.1</b> HAS and vasopressors</a></li>
<li class="chapter" data-level="4.2" data-path="hepatorenal-syndrome.html"><a href="hepatorenal-syndrome.html#volume-status-in-cirrhosis"><i class="fa fa-check"></i><b>4.2</b> Volume status in cirrhosis</a></li>
</ul></li>
<li class="part"><span><b>II CKD</b></span></li>
<li class="chapter" data-level="5" data-path="ckd-egfr-proteinuria.html"><a href="ckd-egfr-proteinuria.html"><i class="fa fa-check"></i><b>5</b> CKD, eGFR, proteinuria</a>
<ul>
<li class="chapter" data-level="5.1" data-path="ckd-egfr-proteinuria.html"><a href="ckd-egfr-proteinuria.html#egfr"><i class="fa fa-check"></i><b>5.1</b> eGFR</a></li>
<li class="chapter" data-level="5.2" data-path="ckd-egfr-proteinuria.html"><a href="ckd-egfr-proteinuria.html#association-of-egfr-and-proteinuria-with-hard-outcomes"><i class="fa fa-check"></i><b>5.2</b> Association of eGFR and proteinuria with hard outcomes</a></li>
<li class="chapter" data-level="5.3" data-path="ckd-egfr-proteinuria.html"><a href="ckd-egfr-proteinuria.html#estimating-risk-of-ckd-progression"><i class="fa fa-check"></i><b>5.3</b> Estimating risk of CKD progression</a></li>
<li class="chapter" data-level="5.4" data-path="ckd-egfr-proteinuria.html"><a href="ckd-egfr-proteinuria.html#competing-risk-of-death"><i class="fa fa-check"></i><b>5.4</b> Competing risk of death</a></li>
</ul></li>
<li class="chapter" data-level="6" data-path="slowing-ckd-progression.html"><a href="slowing-ckd-progression.html"><i class="fa fa-check"></i><b>6</b> Slowing CKD progression</a>
<ul>
<li class="chapter" data-level="6.1" data-path="slowing-ckd-progression.html"><a href="slowing-ckd-progression.html#lifestyle-measures"><i class="fa fa-check"></i><b>6.1</b> Lifestyle measures</a></li>
<li class="chapter" data-level="6.2" data-path="slowing-ckd-progression.html"><a href="slowing-ckd-progression.html#ABP_CKD"><i class="fa fa-check"></i><b>6.2</b> Does blood pressure reduction delay <strong>progression of kidney disease</strong>?</a></li>
<li class="chapter" data-level="6.3" data-path="slowing-ckd-progression.html"><a href="slowing-ckd-progression.html#rasi-progression-in-non-diabetic-disease"><i class="fa fa-check"></i><b>6.3</b> RASi &amp; progression in non-diabetic disease</a>
<ul>
<li class="chapter" data-level="6.3.1" data-path="slowing-ckd-progression.html"><a href="slowing-ckd-progression.html#starting-rasi"><i class="fa fa-check"></i><b>6.3.1</b> Starting RASi</a></li>
<li class="chapter" data-level="6.3.2" data-path="slowing-ckd-progression.html"><a href="slowing-ckd-progression.html#stopping-rasi"><i class="fa fa-check"></i><b>6.3.2</b> Stopping RASi</a></li>
</ul></li>
<li class="chapter" data-level="6.4" data-path="slowing-ckd-progression.html"><a href="slowing-ckd-progression.html#SGLT_CKD"><i class="fa fa-check"></i><b>6.4</b> SGLT2i</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="diabetic-kidney-disease.html"><a href="diabetic-kidney-disease.html"><i class="fa fa-check"></i><b>7</b> Diabetic kidney disease</a>
<ul>
<li class="chapter" data-level="7.1" data-path="diabetic-kidney-disease.html"><a href="diabetic-kidney-disease.html#glycaemic-control"><i class="fa fa-check"></i><b>7.1</b> Glycaemic control</a></li>
<li class="chapter" data-level="7.2" data-path="diabetic-kidney-disease.html"><a href="diabetic-kidney-disease.html#DKD_RASi"><i class="fa fa-check"></i><b>7.2</b> RAS blockade</a></li>
<li class="chapter" data-level="7.3" data-path="diabetic-kidney-disease.html"><a href="diabetic-kidney-disease.html#drasi_DKD"><i class="fa fa-check"></i><b>7.3</b> Dual RAAS blockade</a></li>
<li class="chapter" data-level="7.4" data-path="diabetic-kidney-disease.html"><a href="diabetic-kidney-disease.html#SGLT_DKD"><i class="fa fa-check"></i><b>7.4</b> SGLTi</a></li>
<li class="chapter" data-level="7.5" data-path="diabetic-kidney-disease.html"><a href="diabetic-kidney-disease.html#glp1ra"><i class="fa fa-check"></i><b>7.5</b> GLP1ra</a></li>
<li class="chapter" data-level="7.6" data-path="diabetic-kidney-disease.html"><a href="diabetic-kidney-disease.html#four-pillars"><i class="fa fa-check"></i><b>7.6</b> Four pillars</a></li>
</ul></li>
<li class="chapter" data-level="8" data-path="renal-anaemia.html"><a href="renal-anaemia.html"><i class="fa fa-check"></i><b>8</b> Renal anaemia</a>
<ul>
<li class="chapter" data-level="8.1" data-path="renal-anaemia.html"><a href="renal-anaemia.html#erythropoetin"><i class="fa fa-check"></i><b>8.1</b> Erythropoetin</a></li>
<li class="chapter" data-level="8.2" data-path="renal-anaemia.html"><a href="renal-anaemia.html#iron"><i class="fa fa-check"></i><b>8.2</b> Iron</a></li>
</ul></li>
<li class="chapter" data-level="9" data-path="ckd-mbd.html"><a href="ckd-mbd.html"><i class="fa fa-check"></i><b>9</b> CKD-MBD</a>
<ul>
<li class="chapter" data-level="9.1" data-path="ckd-mbd.html"><a href="ckd-mbd.html#cinacalcet"><i class="fa fa-check"></i><b>9.1</b> Cinacalcet</a></li>
<li class="chapter" data-level="9.2" data-path="ckd-mbd.html"><a href="ckd-mbd.html#phosphate-binders"><i class="fa fa-check"></i><b>9.2</b> Phosphate binders</a></li>
</ul></li>
<li class="part"><span><b>III Blood pressure &amp; CVS risk</b></span></li>
<li class="chapter" data-level="10" data-path="HTN.html"><a href="HTN.html"><i class="fa fa-check"></i><b>10</b> Hypertension in the general population</a>
<ul>
<li class="chapter" data-level="10.1" data-path="HTN.html"><a href="HTN.html#rationale-for-treating-htn"><i class="fa fa-check"></i><b>10.1</b> Rationale for treating HTN</a></li>
<li class="chapter" data-level="10.2" data-path="HTN.html"><a href="HTN.html#treatment-thresholds-in-general-population"><i class="fa fa-check"></i><b>10.2</b> Treatment thresholds (in general population)</a></li>
<li class="chapter" data-level="10.3" data-path="HTN.html"><a href="HTN.html#mode-of-intervention"><i class="fa fa-check"></i><b>10.3</b> Mode of intervention</a></li>
<li class="chapter" data-level="10.4" data-path="HTN.html"><a href="HTN.html#special-populations"><i class="fa fa-check"></i><b>10.4</b> Special populations</a></li>
<li class="chapter" data-level="10.5" data-path="HTN.html"><a href="HTN.html#renal-dennervation"><i class="fa fa-check"></i><b>10.5</b> Renal dennervation</a></li>
</ul></li>
<li class="chapter" data-level="11" data-path="cvs-risk-in-the-general-population.html"><a href="cvs-risk-in-the-general-population.html"><i class="fa fa-check"></i><b>11</b> CVS risk in the general population</a>
<ul>
<li class="chapter" data-level="11.1" data-path="cvs-risk-in-the-general-population.html"><a href="cvs-risk-in-the-general-population.html#assessing-risk"><i class="fa fa-check"></i><b>11.1</b> Assessing risk</a></li>
<li class="chapter" data-level="11.2" data-path="cvs-risk-in-the-general-population.html"><a href="cvs-risk-in-the-general-population.html#interventions-to-reduce-risk"><i class="fa fa-check"></i><b>11.2</b> Interventions to reduce risk</a></li>
</ul></li>
<li class="chapter" data-level="12" data-path="cvs-risk-in-ckd.html"><a href="cvs-risk-in-ckd.html"><i class="fa fa-check"></i><b>12</b> CVS risk in CKD</a>
<ul>
<li class="chapter" data-level="12.1" data-path="cvs-risk-in-ckd.html"><a href="cvs-risk-in-ckd.html#statins"><i class="fa fa-check"></i><b>12.1</b> Statins</a></li>
<li class="chapter" data-level="12.2" data-path="cvs-risk-in-ckd.html"><a href="cvs-risk-in-ckd.html#coronary-intervention"><i class="fa fa-check"></i><b>12.2</b> Coronary intervention</a></li>
<li class="chapter" data-level="12.3" data-path="cvs-risk-in-ckd.html"><a href="cvs-risk-in-ckd.html#afib"><i class="fa fa-check"></i><b>12.3</b> AFib</a></li>
</ul></li>
<li class="chapter" data-level="13" data-path="renovascular-disease.html"><a href="renovascular-disease.html"><i class="fa fa-check"></i><b>13</b> Renovascular disease</a></li>
<li class="part"><span><b>IV BODY FLUIDS</b></span></li>
<li class="chapter" data-level="14" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html"><i class="fa fa-check"></i><b>14</b> Fluids, electrolytes &amp; acid-base</a>
<ul>
<li class="chapter" data-level="14.1" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#hyponatraemia"><i class="fa fa-check"></i><b>14.1</b> Hyponatraemia</a></li>
<li class="chapter" data-level="14.2" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#hyperkalaemia"><i class="fa fa-check"></i><b>14.2</b> Hyperkalaemia</a></li>
<li class="chapter" data-level="14.3" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#fluids"><i class="fa fa-check"></i><b>14.3</b> IV fluid therapy</a></li>
<li class="chapter" data-level="14.4" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#diuretic-therapy"><i class="fa fa-check"></i><b>14.4</b> Diuretic therapy</a></li>
<li class="chapter" data-level="14.5" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#metabolic-acidosis"><i class="fa fa-check"></i><b>14.5</b> Metabolic acidosis</a>
<ul>
<li class="chapter" data-level="14.5.1" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#acidosis-of-ckd"><i class="fa fa-check"></i><b>14.5.1</b> Acidosis of CKD</a></li>
<li class="chapter" data-level="14.5.2" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#renal-tubular-acidosis"><i class="fa fa-check"></i><b>14.5.2</b> Renal tubular acidosis</a></li>
<li class="chapter" data-level="14.5.3" data-path="fluids-electrolytes-acid-base.html"><a href="fluids-electrolytes-acid-base.html#severe-metabolic-acidosis"><i class="fa fa-check"></i><b>14.5.3</b> Severe metabolic acidosis</a></li>
</ul></li>
</ul></li>
<li class="part"><span><b>V SPECIFIC KIDNEY DISEASES</b></span></li>
<li class="chapter" data-level="15" data-path="glomerular-disease.html"><a href="glomerular-disease.html"><i class="fa fa-check"></i><b>15</b> Glomerular disease</a>
<ul>
<li class="chapter" data-level="15.1" data-path="glomerular-disease.html"><a href="glomerular-disease.html#proteinuria"><i class="fa fa-check"></i><b>15.1</b> Proteinuria</a></li>
<li class="chapter" data-level="15.2" data-path="glomerular-disease.html"><a href="glomerular-disease.html#igan"><i class="fa fa-check"></i><b>15.2</b> IgAN</a></li>
<li class="chapter" data-level="15.3" data-path="glomerular-disease.html"><a href="glomerular-disease.html#membranous"><i class="fa fa-check"></i><b>15.3</b> Membranous</a></li>
<li class="chapter" data-level="15.4" data-path="glomerular-disease.html"><a href="glomerular-disease.html#minimal-change"><i class="fa fa-check"></i><b>15.4</b> Minimal change</a></li>
<li class="chapter" data-level="15.5" data-path="glomerular-disease.html"><a href="glomerular-disease.html#fsgs"><i class="fa fa-check"></i><b>15.5</b> FSGS</a></li>
<li class="chapter" data-level="15.6" data-path="glomerular-disease.html"><a href="glomerular-disease.html#Apol1"><i class="fa fa-check"></i><b>15.6</b> APOL1 nephropathy</a></li>
<li class="chapter" data-level="15.7" data-path="glomerular-disease.html"><a href="glomerular-disease.html#ahus"><i class="fa fa-check"></i><b>15.7</b> aHUS</a></li>
</ul></li>
<li class="chapter" data-level="16" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html"><i class="fa fa-check"></i><b>16</b> ANCA vasculitis</a>
<ul>
<li class="chapter" data-level="16.1" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#induction"><i class="fa fa-check"></i><b>16.1</b> Induction</a>
<ul>
<li class="chapter" data-level="16.1.1" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#glucocorticoids-plasma-exchange"><i class="fa fa-check"></i><b>16.1.1</b> Glucocorticoids &amp; Plasma-exchange</a></li>
<li class="chapter" data-level="16.1.2" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#cyclophosphamide"><i class="fa fa-check"></i><b>16.1.2</b> Cyclophosphamide</a></li>
<li class="chapter" data-level="16.1.3" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#rituximab"><i class="fa fa-check"></i><b>16.1.3</b> Rituximab</a></li>
<li class="chapter" data-level="16.1.4" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#other-agents"><i class="fa fa-check"></i><b>16.1.4</b> Other agents</a></li>
</ul></li>
<li class="chapter" data-level="16.2" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#maintenance"><i class="fa fa-check"></i><b>16.2</b> Maintenance</a></li>
<li class="chapter" data-level="16.3" data-path="anca-vasculitis.html"><a href="anca-vasculitis.html#adjunctive-therapies"><i class="fa fa-check"></i><b>16.3</b> Adjunctive therapies</a></li>
</ul></li>
<li class="chapter" data-level="17" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html"><i class="fa fa-check"></i><b>17</b> Lupus nephritis</a>
<ul>
<li class="chapter" data-level="17.1" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html#induction-1"><i class="fa fa-check"></i><b>17.1</b> Induction</a></li>
<li class="chapter" data-level="17.2" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html#maintenance-adjunctive-rx"><i class="fa fa-check"></i><b>17.2</b> Maintenance &amp; adjunctive Rx</a></li>
<li class="chapter" data-level="17.3" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html#newer-therapies"><i class="fa fa-check"></i><b>17.3</b> Newer therapies</a>
<ul>
<li class="chapter" data-level="17.3.1" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html#b-cell-therapies"><i class="fa fa-check"></i><b>17.3.1</b> B-cell therapies</a></li>
<li class="chapter" data-level="17.3.2" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html#cnis"><i class="fa fa-check"></i><b>17.3.2</b> CNIs</a></li>
</ul></li>
<li class="chapter" data-level="17.4" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html#glucocorticoid-toxicity"><i class="fa fa-check"></i><b>17.4</b> Glucocorticoid toxicity</a></li>
<li class="chapter" data-level="17.5" data-path="lupus-nephritis.html"><a href="lupus-nephritis.html#contraception"><i class="fa fa-check"></i><b>17.5</b> Contraception</a></li>
</ul></li>
<li class="chapter" data-level="18" data-path="adpkd.html"><a href="adpkd.html"><i class="fa fa-check"></i><b>18</b> ADPKD</a>
<ul>
<li class="chapter" data-level="18.1" data-path="adpkd.html"><a href="adpkd.html#blood-pressure-targets-and-rasi"><i class="fa fa-check"></i><b>18.1</b> Blood pressure targets and RASi</a></li>
<li class="chapter" data-level="18.2" data-path="adpkd.html"><a href="adpkd.html#vasopressin-antagonist-therapy"><i class="fa fa-check"></i><b>18.2</b> Vasopressin antagonist therapy</a></li>
</ul></li>
<li class="chapter" data-level="19" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html"><i class="fa fa-check"></i><b>19</b> Miscellaneous conditions</a>
<ul>
<li class="chapter" data-level="19.1" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html#myeloma"><i class="fa fa-check"></i><b>19.1</b> Myeloma</a></li>
<li class="chapter" data-level="19.2" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html#pregnancy"><i class="fa fa-check"></i><b>19.2</b> Pregnancy</a></li>
<li class="chapter" data-level="19.3" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html#ain"><i class="fa fa-check"></i><b>19.3</b> AIN</a></li>
<li class="chapter" data-level="19.4" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html#tuberous-sclerosis"><i class="fa fa-check"></i><b>19.4</b> Tuberous sclerosis</a></li>
<li class="chapter" data-level="19.5" data-path="miscellaneous-conditions.html"><a href="miscellaneous-conditions.html#other"><i class="fa fa-check"></i><b>19.5</b> Other</a></li>
</ul></li>
<li class="part"><span><b>VI DIALYSIS</b></span></li>
<li class="chapter" data-level="20" data-path="acute_RRT.html"><a href="acute_RRT.html"><i class="fa fa-check"></i><b>20</b> Acute dialysis</a>
<ul>
<li class="chapter" data-level="20.1" data-path="acute_RRT.html"><a href="acute_RRT.html#dose"><i class="fa fa-check"></i><b>20.1</b> Dose</a></li>
<li class="chapter" data-level="20.2" data-path="acute_RRT.html"><a href="acute_RRT.html#timing"><i class="fa fa-check"></i><b>20.2</b> Timing</a></li>
</ul></li>
<li class="chapter" data-level="21" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html"><i class="fa fa-check"></i><b>21</b> Chronic dialysis</a>
<ul>
<li class="chapter" data-level="21.1" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html#chronic-haemodialysis"><i class="fa fa-check"></i><b>21.1</b> Chronic Haemodialysis</a>
<ul>
<li class="chapter" data-level="21.1.1" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html#modality"><i class="fa fa-check"></i><b>21.1.1</b> Modality</a></li>
<li class="chapter" data-level="21.1.2" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html#dose-1"><i class="fa fa-check"></i><b>21.1.2</b> Dose</a></li>
<li class="chapter" data-level="21.1.3" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html#initiation"><i class="fa fa-check"></i><b>21.1.3</b> Initiation</a></li>
</ul></li>
<li class="chapter" data-level="21.2" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html#peritoneal-dialysis"><i class="fa fa-check"></i><b>21.2</b> Peritoneal Dialysis</a></li>
<li class="chapter" data-level="21.3" data-path="chronic-dialysis.html"><a href="chronic-dialysis.html#conservative-care"><i class="fa fa-check"></i><b>21.3</b> Conservative care</a></li>
</ul></li>
<li class="part"><span><b>VII TRANSPLANT</b></span></li>
<li class="chapter" data-level="22" data-path="transplant---donors.html"><a href="transplant---donors.html"><i class="fa fa-check"></i><b>22</b> Transplant - donors</a>
<ul>
<li class="chapter" data-level="22.1" data-path="transplant---donors.html"><a href="transplant---donors.html#donor-types"><i class="fa fa-check"></i><b>22.1</b> Donor types</a></li>
<li class="chapter" data-level="22.2" data-path="transplant---donors.html"><a href="transplant---donors.html#donor-aki"><i class="fa fa-check"></i><b>22.2</b> Donor AKI</a></li>
<li class="chapter" data-level="22.3" data-path="transplant---donors.html"><a href="transplant---donors.html#ischaemic-time"><i class="fa fa-check"></i><b>22.3</b> Ischaemic time</a></li>
</ul></li>
<li class="chapter" data-level="23" data-path="transplant---immunosuppression-rejection.html"><a href="transplant---immunosuppression-rejection.html"><i class="fa fa-check"></i><b>23</b> Transplant - immunosuppression &amp; rejection</a>
<ul>
<li class="chapter" data-level="23.1" data-path="transplant---immunosuppression-rejection.html"><a href="transplant---immunosuppression-rejection.html#immunosuppression"><i class="fa fa-check"></i><b>23.1</b> Immunosuppression</a></li>
<li class="chapter" data-level="23.2" data-path="transplant---immunosuppression-rejection.html"><a href="transplant---immunosuppression-rejection.html#desensitisation"><i class="fa fa-check"></i><b>23.2</b> Desensitisation</a></li>
<li class="chapter" data-level="23.3" data-path="transplant---immunosuppression-rejection.html"><a href="transplant---immunosuppression-rejection.html#rejection"><i class="fa fa-check"></i><b>23.3</b> Rejection</a></li>
</ul></li>
<li class="chapter" data-level="24" data-path="transplant---complications.html"><a href="transplant---complications.html"><i class="fa fa-check"></i><b>24</b> Transplant - complications</a>
<ul>
<li class="chapter" data-level="24.1" data-path="transplant---complications.html"><a href="transplant---complications.html#cmv-disease"><i class="fa fa-check"></i><b>24.1</b> CMV disease</a></li>
<li class="chapter" data-level="24.2" data-path="transplant---complications.html"><a href="transplant---complications.html#statin_Tx"><i class="fa fa-check"></i><b>24.2</b> CVS risk</a></li>
</ul></li>
<li class="part"><span><b>VIII OTHER</b></span></li>
<li class="chapter" data-level="25" data-path="historic-trials.html"><a href="historic-trials.html"><i class="fa fa-check"></i><b>25</b> Historic trials</a></li>
<li class="chapter" data-level="26" data-path="seminal-basic-science.html"><a href="seminal-basic-science.html"><i class="fa fa-check"></i><b>26</b> Seminal basic science</a></li>
<li class="chapter" data-level="27" data-path="other-non-renal-specialties.html"><a href="other-non-renal-specialties.html"><i class="fa fa-check"></i><b>27</b> Other (non-renal) specialties</a>
<ul>
<li class="chapter" data-level="27.1" data-path="other-non-renal-specialties.html"><a href="other-non-renal-specialties.html#critical-care"><i class="fa fa-check"></i><b>27.1</b> Critical care</a>
<ul>
<li class="chapter" data-level="27.1.1" data-path="other-non-renal-specialties.html"><a href="other-non-renal-specialties.html#sepsis"><i class="fa fa-check"></i><b>27.1.1</b> Sepsis</a></li>
</ul></li>
<li class="chapter" data-level="27.2" data-path="other-non-renal-specialties.html"><a href="other-non-renal-specialties.html#cardio"><i class="fa fa-check"></i><b>27.2</b> Cardiology</a></li>
<li class="chapter" data-level="27.3" data-path="other-non-renal-specialties.html"><a href="other-non-renal-specialties.html#haematology"><i class="fa fa-check"></i><b>27.3</b> Haematology</a></li>
</ul></li>
<li class="divider"></li>
<li><a href="https://github.com/rstudio/bookdown" target="blank">Published with bookdown</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">LATINART</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="fluids-electrolytes-acid-base" class="section level1 hasAnchor" number="14">
<h1><span class="header-section-number">Chapter 14</span> Fluids, electrolytes &amp; acid-base<a href="fluids-electrolytes-acid-base.html#fluids-electrolytes-acid-base" class="anchor-section" aria-label="Anchor link to header"></a></h1>
<div id="hyponatraemia" class="section level2 hasAnchor" number="14.1">
<h2><span class="header-section-number">14.1</span> Hyponatraemia<a href="fluids-electrolytes-acid-base.html#hyponatraemia" class="anchor-section" aria-label="Anchor link to header"></a></h2>

<div class="box_landmark">
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/3674097"><strong>Chung et al.</strong></a> (1987): <img src="Logo_OBS.png" style="height:1.2em" /> <img src="Logo_SEM.png" style="height:1.2em" /> - UNa discriminates between hypovolaemic (UNa ~18 mM) and eu-volaemic (UNa ~72 mM) hyponatraemia.</p>
</div>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/17105757"><strong>SALT-1 &amp; SALT-2</strong></a> (2006): <img src="Logo_RCT.png" style="height:1.2em" /> - tolvaptan <em>vs.</em> placebo for eu- or hyper-volaemia hyponatraemia. Tolvaptan was effective at raising serum Na<sup>+</sup> in the short term (up to 30 days).</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/17384437"><strong>EVEREST Outcome</strong></a> (2007): <img src="Logo_RCT.png" style="height:1.2em" /> - tolvaptan <em>vs.</em> placebo for patients hospitalised with heart failure. Tolvaptan had beneficial effects on short-term fluid-electrolyte status but no effect on long-term mortality or heart-failure morbidity outcomes.<br />
<a href="https://pubmed.ncbi.nlm.nih.gov/36396331/"><strong>SGLT2i in SIAD</strong></a> (2022): <img src="Logo_RCT.png" style="height:1.2em" /> - empagliflozin <em>vs.</em> placebo in chronic SIAD (n = 14, cross-over, blind RCT). Baseline Na 130 mM. After 4 weeks, improvements in serum Na and cognitive function scores in this small study.</p>
</div>
<div id="hyperkalaemia" class="section level2 hasAnchor" number="14.2">
<h2><span class="header-section-number">14.2</span> Hyperkalaemia<a href="fluids-electrolytes-acid-base.html#hyperkalaemia" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/25415805"><strong>OPAL-HK</strong></a> (2015): <img src="Logo_RCT.png" style="height:1.2em" /> - patiromer <em>vs.</em> placebo in patients with CKD on RASi. Patiromer was effective at preventing hyperkalaemia.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/25415807"><strong>Packham et al.</strong></a> (2015): <img src="Logo_RCT.png" style="height:1.2em" /> - ZS-9 (zirconium cyclosilicate) <em>vs.</em> placebo in hyperkalaemia. ZS-9 was effective at lowering potassium levels.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/31533906"><strong>AMBER</strong></a> (2019): <img src="Logo_RCT.png" style="height:1.2em" /> - patiromer <em>vs.</em> placebo in patients with CKD and resistant HTN being treated with open-label spironolactone. At 12 weeks, more patients in the patiromer group remained on spironolactone (86 <em>vs.</em> 66 %). Differences in blood pressure / proteinuria not determined.</p>
</div>
<div id="fluids" class="section level2 hasAnchor" number="14.3">
<h2><span class="header-section-number">14.3</span> IV fluid therapy<a href="fluids-electrolytes-acid-base.html#fluids" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/15163774"><strong>SAFE</strong></a> (2004): <img src="Logo_RCT.png" style="height:1.2em" /> - 4% HAS <em>vs.</em> 0.9% NaCl in ITU. No difference in mortality at 28 days.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/16714767"><strong>FACCT: fluids and catheters treatment trial</strong></a> (2006): <img src="Logo_RCT.png" style="height:1.2em" /> - conservative <em>vs.</em> liberal fluid strategy in acute lung injury. Primary outcome was death at 60 days. No difference between groups in primary outcome but conservative strategy shortened duration of ventilation / ITU stay.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/21615299"><strong>FEAST</strong></a> (2011): <img src="Logo_RCT.png" style="height:1.2em" /> – IV fluid bolus <em>vs.</em> no fluid bolus in children with severe febrile illness in East Africa (57% malaria). 48-hr mortality was higher in the fluid bolus group.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/29485925"><strong>SMART</strong></a> (2018): <img src="Logo_RCT.png" style="height:1.2em" /> - balanced crystalloids <em>vs.</em> 0.9% NaCl in critically ill adults. Primary outcome was composite of death, RRT or persistant SCr &gt; 200% baseline. Balanced crystalloid group fared better.</p>

<div class="box_landmark">
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/29485926"><strong>SALT-ED</strong></a> (2018): <img src="Logo_RCT.png" style="height:1.2em" /> <img src="Logo_SEM.png" style="height:1.2em" /> - balanced crystalloids <em>vs.</em> 0.9% NaCl in non-critically ill adults. Primary outcome was composite of in-hospital mortality and length-of-stay to 28 days. No difference between groups (but less AKI in the balanced crystalloids group). Median volume of fluids was only ~1L.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/29742967"><strong>RELIEF</strong></a> (2018): <img src="Logo_RCT.png" style="height:1.2em" /> <img src="Logo_SEM.png" style="height:1.2em" /> - restrictive <em>vs.</em> liberal peri-operative fluid strategy. No difference in the primary outcome (disability-free survival at 1 yr); more AKI in the restrictive group.</p>
</div>
</div>
<div id="diuretic-therapy" class="section level2 hasAnchor" number="14.4">
<h2><span class="header-section-number">14.4</span> Diuretic therapy<a href="fluids-electrolytes-acid-base.html#diuretic-therapy" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/4697939"><strong>Dikshit et al</strong></a> (1973): <img src="Logo_PHY.png" style="height:1.2em" /> <img src="Logo_SEM.png" style="height:1.2em" /> - haemodynamic parameters studied in 20 patients given IV furosemide for LV failure after acute MI. Within 15 mins, there was a 50% increase in peripheral venous capacitance and a 25% fall in LV filling pressure (PCWP), preceding any increase in urine output. Therefore the immediate beneficial effects of furosemide are mediated by venodilatation.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/23131078"><strong>CARESS-HF</strong></a> (2012): <img src="Logo_RCT.png" style="height:1.2em" /> - diuretics <em>vs.</em> ultrafiltration in acute decompensated heart failure. No difference in weight loss at 96 hrs; UF group had worse renal function and more adverse events.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/21366472"><strong>DOSE</strong></a> (2011): <img src="Logo_RCT.png" style="height:1.2em" /> with factorial design: bolus <em>vs.</em> infusion furosemide and low- vs. high- dose in acute decompensated heart failure. No significant differences in symptoms or SCr at 72 hrs in any group.</p>
</div>
<div id="metabolic-acidosis" class="section level2 hasAnchor" number="14.5">
<h2><span class="header-section-number">14.5</span> Metabolic acidosis<a href="fluids-electrolytes-acid-base.html#metabolic-acidosis" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<div id="acidosis-of-ckd" class="section level3 hasAnchor" number="14.5.1">
<h3><span class="header-section-number">14.5.1</span> Acidosis of CKD<a href="fluids-electrolytes-acid-base.html#acidosis-of-ckd" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/19608703"><strong>de Brito-Ashurst et al.</strong></a> (2009): <img src="Logo_RCT.png" style="height:1.2em" /> - oral NaHCO<sub>3</sub> <em>vs.</em> standard care for 2 yrs in acidaemic CKD IV. NaHCO<sub>3</sub> slowed rate of CrCl decline.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/20445497"><strong>Mahajan et al.</strong></a> (2010): <img src="Logo_RCT.png" style="height:1.2em" /> - oral NaHCO<sub>3</sub> <em>vs.</em> placebo for 5 yrs in hypertensive CKD III. NaHCO<sub>3</sub> slowed rate of eGFR decline.</p>
</div>
<div id="renal-tubular-acidosis" class="section level3 hasAnchor" number="14.5.2">
<h3><span class="header-section-number">14.5.2</span> Renal tubular acidosis<a href="fluids-electrolytes-acid-base.html#renal-tubular-acidosis" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/17410104"><strong>FF test</strong></a> (2007): <img src="Logo_PHY.png" style="height:1.2em" /> - furosemide-fludrocortisone test to diagnose dRTA.</p>
</div>
<div id="severe-metabolic-acidosis" class="section level3 hasAnchor" number="14.5.3">
<h3><span class="header-section-number">14.5.3</span> Severe metabolic acidosis<a href="fluids-electrolytes-acid-base.html#severe-metabolic-acidosis" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/29910040"><strong>BICAR-ICU</strong></a> (2018): <img src="Logo_RCT.png" style="height:1.2em" /> - IV 4.2% NaHCO<sub>3</sub> <em>vs</em> placebo in severe metabolic acidaemia (pH &lt;7.2). No effect on composite primary outcome overall - but NaHCO<sub>3</sub> did improve 28-day survival in (pre-specified) subgroup with AKI.</p>

</div>
</div>
</div>



            </section>

          </div>
        </div>
      </div>
<a href="renovascular-disease.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="glomerular-disease.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": null,
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 1
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": null,
"search": {
"engine": "fuse",
"options": null
},
"toc": {
"collapse": "section"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "true";
    if (src === "" || src === "true") src = "https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.9/latest.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:")
      if (/^https?:/.test(src))
        src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
